Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908589 | 0.92 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL4916376 | 0.91 | TRPV1 (0.60) | TRPV1ABCG2 | |
| SCHEMBL4908491 | 0.91 | TRPV1 (0.51) | TRPV1ABCG2 | |
| SCHEMBL4917928 | 0.91 | TRPV1 (0.52) | TRPV1ABCG2 | |
| SCHEMBL4915278 | 0.90 | TRPV1 (0.62) | TRPV1ABCG2 | |
| SCHEMBL4917987 | 0.90 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL4916616 | 0.89 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL4908179 | 0.88 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL4916333 | 0.88 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL4920761 | 0.87 | TRPV1 (0.46) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | claimed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | claimed |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | claimed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | claimed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | US | disclosed |
| US-7074799-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | TRPV1 244/4885ABCG2 300/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | TRPV1 36/4885ABCG2 654/4885 |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | TRPV1, CNR2, NTRK1 | TRPV1 1/4885ABCG2 1958/4885 |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 244/4885ABCG2 300/4885 |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | GPR27, GPR88, MUSK | TRPV1 211/4885ABCG2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.